BBNX DEADLINE: ROSEN, LEADING TRIAL COUNSEL, Encourages Beta Bionics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - BBNX

A securities class action lawsuit has been filed against Beta Bionics, Inc. for allegedly making false and misleading statements about its iLet Bionic Pancreas insulin pump. The FDA raised serious concerns about the device malfunctioning and dosing patients with dangerously high insulin levels, causing hypoglycemic events. The lawsuit claims thousands of complaints were filed with the FDA, contrary to defendants' assertions that they were benign. The lead plaintiff deadline is November 3, 2026.